Browse SLC6A6

Summary
SymbolSLC6A6
Namesolute carrier family 6 (neurotransmitter transporter), member 6
Aliases TAUT; taurine transporter; solute carrier family 6 (neurotransmitter transporter, taurine), member 6; Solute ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00209 Sodium
Function

Sodium-dependent taurine and beta-alanine transporter. Chloride ions are necessary for optimal uptake.

> Gene Ontology
 
Biological Process GO:0003333 amino acid transmembrane transport
GO:0006520 cellular amino acid metabolic process
GO:0006836 neurotransmitter transport
GO:0006865 amino acid transport
GO:0015734 taurine transport
GO:0015849 organic acid transport
GO:0072348 sulfur compound transport
GO:1903825 organic acid transmembrane transport
GO:1905039 carboxylic acid transmembrane transport
Molecular Function GO:0005326 neurotransmitter transporter activity
GO:0005328 neurotransmitter:sodium symporter activity
GO:0005342 organic acid transmembrane transporter activity
GO:0005343 organic acid:sodium symporter activity
GO:0005368 taurine transmembrane transporter activity
GO:0005369 taurine:sodium symporter activity
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015081 sodium ion transmembrane transporter activity
GO:0015171 amino acid transmembrane transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015293 symporter activity
GO:0015294 solute:cation symporter activity
GO:0015370 solute:sodium symporter activity
GO:0022804 active transmembrane transporter activity
GO:0046873 metal ion transmembrane transporter activity
GO:0046943 carboxylic acid transmembrane transporter activity
GO:1901682 sulfur compound transmembrane transporter activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-425428: Amine compound SLC transporters
R-HSA-425374: Amino acid and oligopeptide SLC transporters
R-HSA-352230: Amino acid transport across the plasma membrane
R-HSA-442660: Na+/Cl- dependent neurotransmitter transporters
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425366: Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
R-HSA-425393: Transport of inorganic cations/anions and amino acids/oligopeptides
Summary
SymbolSLC6A6
Namesolute carrier family 6 (neurotransmitter transporter), member 6
Aliases TAUT; taurine transporter; solute carrier family 6 (neurotransmitter transporter, taurine), member 6; Solute ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC6A6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSLC6A6
Namesolute carrier family 6 (neurotransmitter transporter), member 6
Aliases TAUT; taurine transporter; solute carrier family 6 (neurotransmitter transporter, taurine), member 6; Solute ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC6A6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC6A6
Namesolute carrier family 6 (neurotransmitter transporter), member 6
Aliases TAUT; taurine transporter; solute carrier family 6 (neurotransmitter transporter, taurine), member 6; Solute ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC6A6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9550.00327
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.4090.355
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6240.587
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1180.731
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0730.97
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1780.944
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.430.35
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6350.693
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1850.919
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4330.751
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.230.519
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0130.914
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC6A6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC6A6
Namesolute carrier family 6 (neurotransmitter transporter), member 6
Aliases TAUT; taurine transporter; solute carrier family 6 (neurotransmitter transporter, taurine), member 6; Solute ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC6A6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC6A6
Namesolute carrier family 6 (neurotransmitter transporter), member 6
Aliases TAUT; taurine transporter; solute carrier family 6 (neurotransmitter transporter, taurine), member 6; Solute ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC6A6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC6A6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC6A6
Namesolute carrier family 6 (neurotransmitter transporter), member 6
Aliases TAUT; taurine transporter; solute carrier family 6 (neurotransmitter transporter, taurine), member 6; Solute ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC6A6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC6A6
Namesolute carrier family 6 (neurotransmitter transporter), member 6
Aliases TAUT; taurine transporter; solute carrier family 6 (neurotransmitter transporter, taurine), member 6; Solute ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC6A6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC6A6
Namesolute carrier family 6 (neurotransmitter transporter), member 6
Aliases TAUT; taurine transporter; solute carrier family 6 (neurotransmitter transporter, taurine), member 6; Solute ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC6A6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC6A6
Namesolute carrier family 6 (neurotransmitter transporter), member 6
Aliases TAUT; taurine transporter; solute carrier family 6 (neurotransmitter transporter, taurine), member 6; Solute ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC6A6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.